白云山（00874）今日盘中大涨5.03%，引发市场关注。这波涨势很可能与公司近期发布的2025年半年度报告有关。
根据公告，白云山2025年上半年实现营收418.35亿元，同比增长1.93%；归属于上市公司股东的净利润25.16亿元，同比微降1.31%；基本每股收益1.548元。尽管净利润略有下滑，但公司业绩整体表现稳健。更值得注意的是，公司宣布中期派息每10股4元（含税），这一慷慨的分红政策无疑提振了投资者信心。
除财务数据外，白云山在研发创新方面也取得了显著进展。公司报告期内获得15项药品注册相关批件，并荣获多个国家级和省级奖项。此外，公司还新增了国家级和省级平台，其中由旗下采芝林药业牵头的"广东创新中药制剂转化中试平台"入选工信部首批中试平台，彰显了公司在中药创新领域的领先地位。这些成果可能进一步增强了市场对白云山长期发展前景的信心，推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.